SwePub
Sök i LIBRIS databas

  Utökad sökning

id:"swepub:oai:lup.lub.lu.se:308fa5ad-0013-4958-b944-4fb765460c39"
 

Sökning: id:"swepub:oai:lup.lub.lu.se:308fa5ad-0013-4958-b944-4fb765460c39" > Sequential chemothe...

Sequential chemotherapy/radiotherapy was comparable with concurrent chemoradiotherapy for stage I/II NK/T-cell lymphoma

Kwong, Y. L. (författare)
Queen Mary Hospital
Kim, S. J. (författare)
Sungkyunkwan University
Tse, E. (författare)
Queen Mary Hospital
visa fler...
Oh, S. Y. (författare)
Dong-a University Hospital
Kwak, J. Y. (författare)
Chonbuk National University
Eom, H. S. (författare)
National Cancer Center, Gyeonggi
Do, Y. R. (författare)
Keimyung University
Mun, Y. C. (författare)
Ewha Womans University Mokdong Hospital
Lee, S. R. (författare)
Korea University Ansan Hospital
Shin, H. J. (författare)
Pusan National University Yangsan Hospital
Suh, C. (författare)
Chuang, S. S. (författare)
Lee, Y. S. (författare)
Singapore General Hospital
Lim, S. T. (författare)
National Cancer Centre Singapore
Izutsu, K. (författare)
Suzuki, R. (författare)
Shimane University
Relander, T. (författare)
Lund University,Lunds universitet,Skåne University Hospital
d'Amore, F. (författare)
Aarhus University Hospital
Schmitz, N. (författare)
Asklepios Klinik St. Georg
Jaccard, A. (författare)
University Hospital Of Limoges
Kim, W. S. (författare)
Sungkyunkwan University
visa färre...
 (creator_code:org_t)
Elsevier BV, 2018
2018
Engelska.
Ingår i: Annals of Oncology. - : Elsevier BV. - 0923-7534. ; 29:1, s. 256-263
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Background: In stage I/II natural killer (NK)/T-cell lymphoma, concurrent chemoradiotherapy (CCRT) had previously been shown to result in superior outcome compared with anthracycline-containing regimens, which have since been considered ineffective. The role of CCRT in comparison with approaches employing nonanthracycline-containing chemotherapy (CT) and sequential radiotherapy (RT) in such patients remains to be defined. Patients and methods: Three hundred and three untreated patients (207 men, 96 women; median age: 51, 18-86 years) with stage I/II NK/T-cell lymphoma who had received nonanthracycline-containing regimens were collected from an international consortium and retrospectively analyzed. Treatment included single modality (CT and RT), sequential modalities (CT+RT; RT+CT) and concurrent modalities (CCRT; CCRT+CT). The impact of clinicopathologic parameters and types of treatment on complete response (CR) rate, progression-free-survival (PFS) and overall-survival (OS) was evaluated. Results: For CR, stage (P=0.027), prognostic index for NK/T-cell lymphoma (PINK) (P=0.026) and types of initial treatment (P=0.011) were significant prognostic factors on multivariate analysis. On Cox regression analysis, ECOG performance score (P=0.021) and PINK-EBV DNA (PINK-E) (P=0.002) significantly impacted on PFS; whereas ECOG performance score (P=0.008) and stage (P<0.001) significantly impacted on OS. For comparing CCRT6CT and sequential CT+RT, CCRT6CT patients (n=190) were similar to sequential CT+RT patients (n=54) in all evaluated clinicopathologic parameters except two significantly superior features (higher proportion of undetectable circulating EBV DNA on diagnosis and lower PINK-E scores). Despite more favorable pre-treatment characteristics, CCRT6CT patients had CR rate, PFS and OS comparable with sequential CT+RT patients on multivariate and Cox regression analyses. Conclusions: In stage I/II NK/T-cell lymphomas, when effective chemotherapeutic regimens were used, CCRT and sequential CT+RT gave similar outcome.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cancer and Oncology (hsv//eng)

Nyckelord

Concurrent chemoradiotherapy
Sequential chemotherapy and radiotherapy
Stage I/II NK/T-cell lymphomas

Publikations- och innehållstyp

art (ämneskategori)
ref (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy